Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters











Database
Language
Publication year range
1.
Hum Vaccin Immunother ; 9(3): 636-41, 2013 Mar.
Article in English | MEDLINE | ID: mdl-23354158

ABSTRACT

Italy was one of the first industrialized countries to introduce a program of universal vaccination against hepatitis B in 1991. Twenty years later we verified the impact of universal immunisation on the epidemiology of hepatitis B infection by analyzing the prevalence of specific viral markers (anti-HBs, anti-HBc and HBsAg). The ELISA tests were performed on residual blood samples collected by 0.05% of the resident population aged 1-50 years in Tuscany (Italy). About 63% of subjects aged < 30 years were anti-HBs positive compared to about 25% in older subjects, without differences between genders. About 22% of subjects over 40 years were anti-HBc-positive compared to 5% in the younger age groups. The number of HBsAg-positive subjects was almost 10 fold higher in the unvaccinated age groups than in the cohorts involved in the universal vaccination program. The results of our study show the persisting high anti-HBs reactivity in vaccinated cohorts, while HBV markers related to natural exposure or persistent infection remain remarkably higher in older age groups. This sero-epidemiological study supports with prevalence data the downward incidence trend of acute hepatitis B highlighted by epidemiological surveillance systems, and corroborates the forecast for elimination of hepatitis B in Italy in a few decades.


Subject(s)
Hepatitis B Antibodies/blood , Hepatitis B/epidemiology , Hepatitis B/prevention & control , Vaccination/methods , Adolescent , Adult , Age Factors , Child , Child, Preschool , Cohort Studies , Enzyme-Linked Immunosorbent Assay , Female , Humans , Incidence , Infant , Italy/epidemiology , Male , Middle Aged , Seroepidemiologic Studies , Vaccination/statistics & numerical data , Young Adult
2.
Eur J Public Health ; 22(1): 133-9, 2012 Feb.
Article in English | MEDLINE | ID: mdl-20880991

ABSTRACT

BACKGROUND: As a part of the National Plan for Measles and Congenital Rubella Elimination, a catch-up campaign targeting children aged 7-14 years with Measles-Mumps-Rubella (MMR) vaccine was conducted during 2004-05 in Tuscany, Central Italy. METHODS: To assess the profile of measles and rubella susceptibility, immunoglobulin G antibodies against measles (945 subjects) and rubella (1110 subjects) were detected using two commercial enzyme-linked immunosorbent assay tests in sera from a population aged 1-49 years. RESULTS: Overall immunity towards measles increased in the last years, but the WHO-Euro recommended threshold of susceptibility for elimination was attained only in 2- to 4-year-olds. All fertile women up to 29 years had rates of susceptibility clearly higher than those required by WHO-Euro (5%) to eliminate congenital rubella. Despite the reduction of susceptibility among subjects targeted by the catch-up campaign, continuous efforts to increase immunization coverage are needed to eliminate measles and rubella circulation. Our results are predictive of a high chance of measles and rubella outbreaks because of the accumulation of susceptible individuals. CONCLUSION: Additional catch-up vaccination strategies targeting the adult population (particularly fertile women) are strongly needed to eliminate the risk of measles and congenital rubella syndrome for future generations.


Subject(s)
Measles/prevention & control , Rubella/prevention & control , Adolescent , Adult , Child , Child, Preschool , Enzyme-Linked Immunosorbent Assay , Female , Health Promotion , Humans , Immunization Programs , Immunoglobulin G/blood , Infant , Italy/epidemiology , Male , Measles/epidemiology , Measles-Mumps-Rubella Vaccine/therapeutic use , Middle Aged , Population Surveillance/methods , Rubella/epidemiology , Seroepidemiologic Studies , Young Adult
3.
Proteomics ; 3(6): 937-41, 2003 Jun.
Article in English | MEDLINE | ID: mdl-12833517

ABSTRACT

Since 1989 recombinant human erythropoietin (rhEPO) has been used as a drug for the correction of anemia, but the misuse of rhEPO as an ergogenic agent among athletes is a widespread doping practice. As a consequence there is a need for developing reference methods for the detection of rhEPO in biological fluids, and to be able to differentiate the recombinant from the natural protein. Recombinant human erythropoietin differs from its natural counterpart in the glycidic part of the molecule. Three different commercial recombinant products Epoetin alpha (Eprex, Janssen Cilag), Epoetin beta (Neorecormon, Roche) and Darbepoetin alfa (Nespo, Dompè) have been used to evaluate the performance of two-dimensional gel electrophoresis (2-DE) and mass spectrometry (MS) for the separation of isoforms and the identification of the proteins respectively. All the compounds studied were well separated by means of 2-DE: Epoetin alpha and beta focused in the same isoelectric point region giving rise to six and eight spots respectively, whereas Darbepoetin alfa was found in a more acidic zone with two spots. Results obtained with micro high-performance liquid chromatography-electrospray ionization-time of flight (TOF) MS and matrix-assisted laser desorption/ionization-time of flight MS for the three rhEPOs are reported. These preliminary results suggest that by means of 2-DE and MS it should be possible to reveal the presence of rhEPOs for antidoping purposes.


Subject(s)
Electrophoresis, Gel, Two-Dimensional/methods , Erythropoietin/analogs & derivatives , Erythropoietin/analysis , Mass Spectrometry/methods , Protein Isoforms/analysis , Chromatography, High Pressure Liquid , Darbepoetin alfa , Epoetin Alfa , Erythropoietin/isolation & purification , Humans , Hydrogen-Ion Concentration , Isoelectric Focusing , Protein Isoforms/isolation & purification , Recombinant Proteins , Spectrometry, Mass, Electrospray Ionization , Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization
SELECTION OF CITATIONS
SEARCH DETAIL